The second largest UK drugmaker, who have some involvement with diabetes, will cut a further 6,000 jobs over the next four year period. The news comes in addition to the 7,600 redundancies already announced by AstraZeneca . By 2013, over 13,000 jobs will have gone at the company.
Despite healthy pre-tax profits, chief executive David Brennan was reported as commenting: “The exact outcome is dependent, in part, on the extent of the impact of global economic conditions experienced over the course of the year.”
Although AstraZeneca do have involvement in the diabetes industry, their blockbuster drugs are Nexium, and ulcer treatment and Crestor, a cholesterol drug. AstraZeneca face 9,000 lawsuits alleging that depression drug Seroquel can cause diabetes and other health problems.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…